Curriculum Vitae

Personal information

Marianne FERRERE

Work experience

- July 2025 - Present

Pharmaceutical Quality Assessor

Agence Nationale de Sécurité du Médicament (ANSM), FRANCE

Assessment of the pharmaceutical quality dossier of chemical drug products for regulatory approval

- February 2022 - July 2025

Senior Scientist

IPSEN, FRANCE

Design and optimization of preclinical formulations for new chemical entities, enabling PK, efficacy, and toxicology studies in early drug development

Education and training

- October 2018 - December 2021

PhD degree

Institut Galien Paris Saclay (IGPS), FRANCE

Synthesis and evaluation of hydrophilic polymer prodrugs for the subcutaneous administration of cytotoxic drugs

- September 2015 - August 2018

Chemical Engineer degree

Ecole Nationale Supérieure de Chimie de Paris (Chimie ParisTech, ENSCP)

Education in chemistry, specialization in organic chemistry

Additional information

Publications

- Guerassimoff, Léa & Ferrere, Marianne & Bossion, Amaury & Nicolas, Julien. (2024). Stimuli-sensitive polymer prodrug nanocarriers by reversible-deactivation radical polymerization. Chemical Society reviews. 53. 10.1039/d2cs01060g.
- Guerassimoff, Léa & Ferrere, Marianne & Van Herck, Simon & Dehissi, Samy & Nicolas, Valérie & De Geest, Bruno & Nicolas, Julien. (2024). Thermosensitive polymer prodrug nanoparticles prepared by an all-aqueous nanoprecipitation process and application to combination therapy. Journal of controlled release : official journal of the Controlled Release Society. 369. 10.1016/j.jconrel.2024.03.049.
- Tomasini, Lorenzo & Ferrere, Marianne & Nicolas, Julien. (2024). Subcutaneous drug delivery from nanoscale systems. Nature Reviews Bioengineering. 2. 10.1038/s44222-024-00161-w.
- Bordat, Alexandre & Boissenot, Tanguy & Ibrahim, Nada & Ferrere, Marianne & Levêque, Manon & Potiron, Léa & Denis, Stephanie & Garcia-Argote, Sébastien & Carvalho, Olivia & Cailleau, Catherine & Pieters, Grégory & Tsapis, Nicolas & Nicolas, Julien. (2022). A Polymer Prodrug Strategy to Switch from Intravenous to Subcutaneous Cancer Therapy for Irritant/Vesicant Drugs. Journal of the American Chemical Society. 144. 10.1021/jacs.2c04944.

Projects

Memberships

Other Relevant Information